エピジェネティクス市場 – 2030年までの世界予測

この調査レポートでは、エピジェネティクス市場を、提供（キットおよび試薬、酵素、機器および付属品、ソフトウェアおよびサービス）、方法（DNAメチル化、ヒストン修飾、およびその他の方法）、技術（NGS、PCRおよびqPCR、質量分析、超音波処理、およびその他の技術）、アプリケーション（腫瘍学、代謝性疾患、免疫学、発生生物学、心血管疾患、およびその他のアプリケーション）、製品のエンドユーザー（学術機関および研究機関、製薬およびバイオテクノロジー企業、病院および診療所、および契約研究機関）、サービスのエンドユーザー（学術機関および研究機関、製薬およびバイオテクノロジー企業、および病院および診療所）および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、およびアフリカ）別に分類しています。
本レポートは、エピジェネティクス市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を提供しています。主要業界プレーヤーを包括的に分析し、事業概要、ソリューション、サービス、主要戦略、新製品・サービスの発売、買収、エピジェネティクス市場に関連する最近の動向に関する洞察を提供しています。また、エピジェネティクス業界のエコシステムにおける新興企業の競合分析も網羅しています。

本レポートは、市場全体とそのサブセグメントの収益予測を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社の効果的なポジショニングと適切な市場開拓戦略の策定に役立つ洞察を得るのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

世界のエピジェネティクス市場規模は、2025年の22億4,000万米ドルから2030年には42億9,000万米ドルに達し、予測期間中は年平均成長率（CAGR）13.9%で成長すると予測されています。シーケンシングのコストと時間の低下、エピジェネティクスにおける技術の進歩、そしてエピジェネティック医薬品および診断薬への需要の高まりといった要因が市場の成長を牽引しています。しかしながら、毒物学におけるエピゲノムデータの応用が限られていること、そしてデータのプライバシーとセキュリティに関する懸念が、市場拡大の足かせとなっています。

The global epigenetics market size is projected to reach USD 4.29 billion by 2030 from USD 2.24 billion in 2025, at a CAGR of 13.9% during the forecast period. Factors such as declining sequencing costs and time, along with technological advancements in epigenetics, and a growing demand for epigenetic drugs and diagnostics drive market growth; however, limited applications of epigenomic data in toxicology, along with data privacy and security concerns, restrain market expansion.

“The PCR & qPCR market is likely to grow at a faster pace.”

The global epigenetics market is categorized by technology into next-generation sequencing (NGS), polymerase chain reaction (PCR) & quantitative PCR (qPCR), mass spectrometry, sonication, and other methodologies. Notably, the PCR & qPCR segment is projected to exhibit significant compound annual growth rate (CAGR). The rising utilization of methylation-specific PCR techniques enhances the sensitivity and specificity of detecting epigenetic modifications, which is anticipated to drive growth in this segment.

“DNA methylation dominated the method segment.”

The epigenetics market is categorized by methodology into several segments, primarily DNA methylation, histone modifications, and other techniques. In 2024, DNA methylation dominated the market, primarily due to its established efficacy in cancer research applications. Furthermore, alternative methodologies—including non-coding RNA analysis and chromatin remodeling—are anticipated to exhibit the highest CAGR throughout the forecast period. This is driven by an increasing focus on innovative epigenetic mechanisms and their prospective roles in diagnostics and therapeutic development.

“Asia Pacific region is estimated to show fastest growth rate.”

On the basis of region, the flow cytometry market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, North America accounted for the major share of the epigenetics market. The Asia Pacific region is projected to experience strong growth during the forecast period, fueled by ongoing improvements in healthcare infrastructure across emerging economies. This market is further boosted by strategic collaborations, partnerships, expansions, and agreements initiated by regional industry players.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25%
• By Region: North America -35%, Europe – 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Danaher (US)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories Inc. (US)
• Promega Corporation (US)
• Revvity (US)
• Qiagen (Germany)
• New England Biolabs (US)
• Zymo Research Corporation (US)
• Hologic Diagenode (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• EpiGentek Group Inc. (US)

Research Coverage:

This research report categorizes epigenetics market by offering (kits & reagents, enzymes, instruments & accessories, software, and services), method (DNA methylation, Histone modification, and other methods), technology (NGS, PCR & qPCR, mass spectrometry, sonication, and other technologies), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, and other applications), end user for product (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), end user for service (academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report’s scope includes detailed information about the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, solutions, and services; key strategies; new product and service launches, acquisitions, and recent developments related to the epigenetics market. This report also covers the competitive analysis of upcoming startups in the epigenetics industry ecosystem.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing estimates of revenue for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key Drivers (declining sequencing costs & time, expansion of population screening programs, technological advancements in epigenetics research, and rising demand for epigenetic drugs & epigenetics-based diagnostics), restraints (limited applications of epigenomic data in toxicology and data privacy concerns and security issues), opportunities (emerging applications of epigenetics and integration of multi-omics), and challenges (concerns regarding quality of antibodies and challenges associated with epigenetic editing) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the epigenetics market.
• Market Development: The report provides comprehensive information about lucrative markets and analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), among others offering products and services for epigenetics market. Other companies include EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), among others, for the epigenetics market.

Table of Contents

1               INTRODUCTION              42

1.1           STUDY OBJECTIVES       42

1.2           MARKET DEFINITION   42

1.3           STUDY SCOPE   43

1.3.1        MARKET SEGMENTATION AND REGIONAL SCOPE                 43

1.3.2        INCLUSIONS AND EXCLUSIONS 44

1.3.3        YEARS CONSIDERED      44

1.4           CURRENCY CONSIDERED            45

1.5           STAKEHOLDERS               45

1.6           SUMMARY OF CHANGES               45

2               RESEARCH METHODOLOGY       47

2.1           RESEARCH DATA              47

2.1.1        SECONDARY DATA          48

2.1.2        PRIMARY DATA 49

2.2           MARKET SIZE ESTIMATION         50

2.2.1        GLOBAL MARKET SIZE ESTIMATION      50

2.2.2        INSIGHTS FROM PRIMARY EXPERTS        53

2.2.3        SEGMENTAL MARKET ASSESSMENT       53

2.3           GROWTH FORECAST MODEL     55

2.4           DATA TRIANGULATION                57

2.5           RESEARCH ASSUMPTIONS           58

2.6           RESEARCH LIMITATIONS             59

2.7           RISK ANALYSIS  59

3               EXECUTIVE SUMMARY  60

4               PREMIUM INSIGHTS       65

4.1           EPIGENETICS MARKET OVERVIEW          65

4.2           NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY  66

4.3           EPIGENETICS PRODUCT MARKET, BY END USER, 2024                 66

4.4           EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              67

5               MARKET OVERVIEW       68

5.1           INTRODUCTION              68

5.2           MARKET DYNAMICS       68

5.2.1        DRIVERS               69

5.2.1.1    Declining sequencing costs and time                 69

5.2.1.2    Growing emphasis on population-scale screening initiatives                 71

5.2.1.3    Technological advancements in epigenetics research     71

5.2.1.4    Rising demand for epigenetic drugs and epigenetic-based therapeutics           72

5.2.2        RESTRAINTS      73

5.2.2.1    Limited applications of epigenomic data in toxicology   73

5.2.2.2    Data privacy concerns and security issues        74

5.2.3        OPPORTUNITIES              74

5.2.3.1    Emerging applications of epigenetics                74

5.2.3.2    Integration of multi-omics  75

5.2.4        CHALLENGES    75

5.2.4.1    Concerns regarding quality of antibodies         75

5.2.4.2    Challenges associated with epigenetic editing 76

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            76

5.4           PRICING ANALYSIS          77

5.4.1        AVERAGE SELLING PRICE TREND, BY KEY PLAYER                 77

5.4.2        AVERAGE SELLING PRICE TREND, BY REGION   80

5.5           VALUE CHAIN ANALYSIS               82

5.6           ECOSYSTEM ANALYSIS  84

5.7           INVESTMENT AND FUNDING SCENARIO               87

5.8           TECHNOLOGY ANALYSIS             89

5.8.1        KEY TECHNOLOGIES     89

5.8.1.1    Single-cell sequencing         89

5.8.1.2    Chromatin immunoprecipitation       89

5.8.2        COMPLEMENTARY TECHNOLOGIES       89

5.8.2.1    DNA methylation microarrays            89

5.8.2.2    CRISPR-based genome editing          89

5.9           PATENT ANALYSIS          90

5.10         TRADE DATA ANALYSIS                92

5.10.1      IMPORT DATA  93

5.10.2      EXPORT DATA  94

5.11         KEY CONFERENCES AND EVENTS, 2025–2026        96

5.12         TARIFF AND REGULATORY LANDSCAPE               97

5.12.1      TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00                 97

5.12.2      REGULATORY FRAMEWORK       98

5.12.3      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             100

5.13         PORTER’S FIVE FORCES ANALYSIS           103

5.13.1      BARGAINING POWER OF SUPPLIERS       104

5.13.2      BARGAINING POWER OF BUYERS             104

5.13.3      THREAT OF NEW ENTRANTS      105

5.13.4      THREAT OF SUBSTITUTES          105

5.13.5      INTENSITY OF COMPETITIVE RIVALRY 105

5.14         KEY STAKEHOLDERS AND BUYING CRITERIA     105

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           106

5.14.2      KEY BUYING CRITERIA  107

5.15         IMPACT OF AI/GEN AI ON EPIGENETICS MARKET                 108

5.15.1      INTRODUCTION              108

5.15.2      MARKET POTENTIAL OF AI IN EPIGENETICS      108

5.15.3      AI USE CASES     108

5.15.4      KEY COMPANIES IMPLEMENTING AI/GEN AI      109

5.15.5      FUTURE OF AI/GEN AI IN EPIGENETICS MARKET                 109

5.16         IMPACT OF 2025 US TARIFF         110

5.16.1      INTRODUCTION              110

5.16.2      KEY TARIFF RATES          110

5.16.3      PRICE IMPACT ANALYSIS             113

5.16.4      KEY IMPACTS ON VARIOUS REGIONS     114

5.16.4.1  US           114

5.16.4.2  Europe   114

5.16.4.3  Asia Pacific            114

5.16.5      END-USE INDUSTRY IMPACT     115

5.16.5.1  Pharmaceutical and biotech companies            115

5.16.5.2  Contract Research Organizations (CROs)       115

5.16.5.3  Academic and research institutes       115

6               EPIGENETICS MARKET, BY OFFERING   116

6.1           INTRODUCTION              117

6.2           KITS & REAGENTS            118

6.2.1        ANTIBODIES      122

6.2.1.1    Growing demand for recombinant antibodies for detection of epigenetic targets to propel market   122

6.2.2        CHIP-SEQUENCING KITS & REAGENTS  125

6.2.2.1    Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market         125

6.2.3        BISULFITE CONVERSION KITS & REAGENTS        129

6.2.3.1    Effective outcomes associated with bisulfite conversion to sustain growth    129

6.2.4        WHOLE-GENOME AMPLIFICATION KITS & REAGENTS                 132

6.2.4.1    Ability to maintain relative proportions of genes in original pool to stimulate growth               132

6.2.5        5-HMC & 5-MC ANALYSIS KITS & REAGENTS        136

6.2.5.1    Introduction of unique kits for 5-mC and 5-hmC analysis to support growth      136

6.2.6        HISTONES           139

6.2.6.1    Emerging importance of chromatin-associated proteins and histones in epigenetic research to bolster growth            139

6.2.7        OTHER KITS & REAGENTS            143

6.3           ENZYMES             147

6.3.1        DNA-MODIFYING ENZYMES       150

6.3.1.1    Broadening applications of DNA methylation to facilitate growth                 150

6.3.2        PROTEIN-MODIFYING ENZYMES              154

6.3.2.1    Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to spur growth    154

6.3.3        OTHER ENZYMES             157

6.4           INSTRUMENTS & ACCESSORIES 160

6.4.1        WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO EXPEDITE GROWTH                160

6.5           SOFTWARE         164

6.5.1        DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROMOTE GROWTH             164

6.6           SERVICES             167

6.6.1        EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE MARKET               167

7               EPIGENETICS MARKET, BY TECHNOLOGY           171

7.1           INTRODUCTION              172

7.2           NEXT-GENERATION SEQUENCING (NGS)             172

7.2.1        INCREASING LAUNCHES OF NEXT-GENERATION SEQUENCING PLATFORMS TO FACILITATE GROWTH    172

7.3           PCR & QPCR       177

7.3.1        RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET                 177

7.4           MASS SPECTROMETRY  181

7.4.1        GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET               181

7.5           SONICATION     185

7.5.1        RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO EXPEDITE GROWTH               185

7.6           OTHER TECHNOLOGIES               188

8               EPIGENETICS MARKET, BY METHOD      192

8.1           INTRODUCTION              193

8.2           DNA METHYLATION      193

8.2.1        INCREASING RESEARCH & DEVELOPMENT ACTIVITIES TO SPUR GROWTH          193

8.3           HISTONE MODIFICATIONS         197

8.3.1        GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 197

8.4           OTHER METHODS           201

9               EPIGENETICS MARKET, BY APPLICATION             204

9.1           INTRODUCTION              205

9.2           ONCOLOGY        205

9.2.1        GROWING INVESTMENT IN EPIGENETIC-BASED RESEARCH TO BOOST MARKET 205

9.3           METABOLIC DISEASES  211

9.3.1        EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR GROWTH      211

9.4           IMMUNOLOGY 214

9.4.1        GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE MARKET               214

9.5           DEVELOPMENTAL BIOLOGY      218

9.5.1        INCREASING RESEARCH ON CELL GROWTH AND DIFFERENTIATION TO PROPEL MARKET              218

9.6           CARDIOVASCULAR DISEASES    221

9.6.1        EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO AID GROWTH             221

9.7           OTHER APPLICATIONS 225

10            EPIGENETICS PRODUCTS MARKET, BY END USER                 229

10.1         INTRODUCTION              230

10.2         ACADEMIC & RESEARCH INSTITUTES    230

10.2.1      INCREASING PUBLIC-PRIVATE COLLABORATIONS TO FAVOR GROWTH              230

10.3         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 234

10.3.1      GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETIC-BASED DRUGS TO FUEL MARKET  234

10.4         HOSPITALS & CLINICS   238

10.4.1      GROWING USE OF PERSONALIZED MEDICINE TO PROPEL MARKET             238

10.5         CONTRACT RESEARCH ORGANIZATIONS             242

10.5.1      INCREASING DEMAND FOR SCALABLE, HIGH-THROUGHPUT EPIGENETICS KITS TO PROMOTE GROWTH                 242

11            EPIGENETICS SERVICE MARKET, BY END USER  246

11.1         INTRODUCTION              247

11.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 247

11.2.1      RISING DEMAND FOR THERAPEUTIC DISCOVERIES TO BOLSTER GROWTH         247

11.3         ACADEMIC & RESEARCH INSTITUTES    251

11.3.1      INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH     251

11.4         HOSPITALS & CLINICS   254

11.4.1      INCREASING INTEGRATION OF EPIGENETIC ASSAYS INTO CLINICAL DIAGNOSTICS, PROGNOSTICS, AND PERSONALIZED MEDICINE TO AID GROWTH     254

12            EPIGENETICS MARKET, BY REGION         258

12.1         INTRODUCTION              259

12.2         NORTH AMERICA             259

12.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 259

12.2.2      US           266

12.2.2.1  Strong network of well-established epigenetic product manufacturers to spur growth             266

12.2.3      CANADA               270

12.2.3.1  Favorable government initiatives to contribute to growth                 270

12.3         EUROPE               275

12.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      275

12.3.2      GERMANY           281

12.3.2.1  Significant investments in next-generation sequencing to bolster growth    281

12.3.3      UK          285

12.3.3.1  Rising acceptance of genome-based diagnostic techniques to support growth      285

12.3.4      FRANCE                290

12.3.4.1  Growing demand for PCR technologies to drive market                 290

12.3.5      ITALY    295

12.3.5.1  High incidence of cancer to expedite growth   295

12.3.6      SPAIN    300

12.3.6.1  Well-established network of research centers and universities to boost market          300

12.3.7      REST OF EUROPE             304

12.4         ASIA PACIFIC     308

12.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 308

12.4.2      CHINA  315

12.4.2.1  High demand for personalized medicine to accelerate growth                 315

12.4.3      JAPAN   320

12.4.3.1  Increasing collaborations between research & academic organizations to favor growth             320

12.4.4      INDIA    325

12.4.4.1  Expanding base of biotechnology facilities to drive market                 325

12.4.5      AUSTRALIA         330

12.4.5.1  Growing hub for epigenetics to propel market                 330

12.4.6      SOUTH KOREA  334

12.4.6.1  Rising burden of chronic diseases to foster growth         334

12.4.7      REST OF ASIA PACIFIC   338

12.5         LATIN AMERICA                342

12.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 342

12.5.2      BRAZIL 347

12.5.2.1  Increasing number of healthcare providers incorporating epigenetic testing to aid growth         347

12.5.3      MEXICO                351

12.5.3.1  Growing adoption of cutting-edge technologies to drive market                 351

12.5.4      REST OF LATIN AMERICA             355

12.6         MIDDLE EAST   359

12.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST                 359

12.6.2      GCC COUNTRIES              365

12.6.2.1  Saudi Arabia          370

12.6.2.1.1                Growing healthcare expenditure to propel market                 370

12.6.2.2  UAE        375

12.6.2.2.1                Increasing collaborations between public and private sectors to spur growth          375

12.6.2.3  Rest of GCC countries         379

12.6.3      REST OF MIDDLE EAST 383

12.7         AFRICA 387

12.7.1      RISING DEMAND FOR TARGETED THERAPIES TO AUGMENT GROWTH      387

12.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        387

13            COMPETITIVE LANDSCAPE         393

13.1         INTRODUCTION              393

13.2         KEY PLAYER STRATEGIES             393

13.3         REVENUE ANALYSIS       395

13.4         MARKET SHARE ANALYSIS           395

13.5         COMPANY VALUATION AND FINANCIAL METRICS                 398

13.6         BRAND/PRODUCT COMPARISON             399

13.6.1      THERMO FISHER SCIENTIFIC INC.            399

13.6.2      ILLUMINA, INC. 399

13.6.3      MERCK KGAA    400

13.6.4      DANAHER            400

13.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 400

13.7.1      STARS   400

13.7.2      EMERGING LEADERS     400

13.7.3      PERVASIVE PLAYERS      400

13.7.4      PARTICIPANTS 401

13.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         402

13.7.5.1  Company footprint               402

13.7.5.2  Region footprint   403

13.7.5.3  Offering footprint 403

13.7.5.4  Method footprint  404

13.7.5.5  Technology footprint           405

13.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        406

13.8.1      PROGRESSIVE COMPANIES         406

13.8.2      RESPONSIVE COMPANIES            406

13.8.3      DYNAMIC COMPANIES  406

13.8.4      STARTING BLOCKS         406

13.8.5      COMPETITIVE BENCHMARKING               408

13.8.5.1  Detailed list of key startups/SMEs    408

13.8.5.2  Competitive benchmarking of key startups/SMEs          409

13.9         COMPETITIVE SCENARIO             409

13.9.1      PRODUCT LAUNCHES   409

13.9.2      DEALS  411

13.9.3      EXPANSIONS     412

14            COMPANY PROFILES      413

14.1         KEY MARKET PLAYERS  413

14.1.1      THERMO FISHER SCIENTIFIC INC.            413

14.1.1.1  Business overview 413

14.1.1.2  Products offered   414

14.1.1.3  Recent developments           416

14.1.1.3.1                Product launches  416

14.1.1.3.2                Deals      417

14.1.1.4  MnM view              417

14.1.1.4.1                Key strengths        417

14.1.1.4.2                Strategic choices   417

14.1.1.4.3                Weaknesses and competitive threats 417

14.1.2      ILLUMINA, INC. 418

14.1.2.1  Business overview 418

14.1.2.2  Products offered   419

14.1.2.3  Recent developments           421

14.1.2.3.1                Product launches  421

14.1.2.3.2                Deals      421

14.1.2.4  MnM view              422

14.1.2.4.1                Key strengths        422

14.1.2.4.2                Strategic choices   422

14.1.2.4.3                Weaknesses and competitive threats 422

14.1.3      MERCK KGAA    423

14.1.3.1  Business overview 423

14.1.3.2  Products offered   424

14.1.3.3  MnM view              426

14.1.3.3.1                Key strengths        426

14.1.3.3.2                Strategic choices   426

14.1.3.3.3                Weaknesses and competitive threats 426

14.1.4      PACBIO 427

14.1.4.1  Business overview 427

14.1.4.2  Products offered   428

14.1.4.3  Recent developments           429

14.1.4.3.1                Product launches  429

14.1.4.3.2                Deals      430

14.1.4.3.3                Expansions             430

14.1.4.4  MnM view              431

14.1.4.4.1                Key strengths        431

14.1.4.4.2                Strategic choices   431

14.1.4.4.3                Weaknesses and competitive threats 431

14.1.5      DANAHER            432

14.1.5.1  Business overview 432

14.1.5.2  Products offered   433

14.1.5.3  Recent developments           435

14.1.5.3.1                Deals      435

14.1.5.4  MnM view              435

14.1.5.4.1                Key strengths        435

14.1.5.4.2                Strategic choices   435

14.1.5.4.3                Weaknesses and competitive threats 435

14.1.6      BIO-RAD LABORATORIES, INC.  436

14.1.6.1  Business overview 436

14.1.6.2  Products offered   437

14.1.7      ACTIVE MOTIF 441

14.1.7.1  Business overview 441

14.1.7.2  Products offered   441

14.1.7.3  Recent developments           444

14.1.7.3.1                Deals      444

14.1.8      NEW ENGLAND BIOLABS              445

14.1.8.1  Business overview 445

14.1.8.2  Products offered   445

14.1.8.3  Recent developments           447

14.1.8.3.1                Product launches  447

14.1.8.3.2                Deals      448

14.1.9      QIAGEN                449

14.1.9.1  Business overview 449

14.1.9.2  Products offered   450

14.1.9.3  Recent developments           451

14.1.9.3.1                Product launches  451

14.1.10   ZYMO RESEARCH CORPORATION             452

14.1.10.1                 Business overview 452

14.1.10.2                 Products offered   452

14.1.10.3                 Recent developments           455

14.1.10.3.1             Product launches  455

14.1.10.3.2             Expansions             455

14.1.10.3.3             Other developments             455

14.1.11   REVVITY               456

14.1.11.1                 Business overview 456

14.1.11.2                 Products offered   457

14.1.11.3                 Recent developments           458

14.1.11.3.1             Deals      458

14.1.12   HOLOGIC, INC. 459

14.1.12.1                 Business overview 459

14.1.12.2                 Products offered   460

14.1.13   F. HOFFMANN-LA ROCHE LTD  463

14.1.13.1                 Business overview 463

14.1.13.2                 Products offered   464

14.1.14   PROMEGA CORPORATION           466

14.1.14.1                 Business overview 466

14.1.14.2                 Products offered   466

14.1.15   EPIGENTEK GROUP INC.               468

14.1.15.1                 Business overview 468

14.1.15.2                 Products offered   468

14.2         OTHER PLAYERS              472

14.2.1      EPICYPHER         472

14.2.2      FIOS GENOMICS               473

14.2.3      GENOMESCAN  474

14.2.4      CREATIVE BIOGENE       475

14.2.5      BPS BIOSCIENCE, INC.   475

14.2.6      ABNOVA CORPORATION              477

14.2.7      CREATIVE DIAGNOSTICS             478

14.2.8      BIOMODAL         479

14.2.9      INTEGRATED DNA TECHNOLOGIES, INC.             480

14.2.10   NOVOGENE CO., LTD.   481

15            APPENDIX           482

15.1         DISCUSSION GUIDE        482

15.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                487

15.3         CUSTOMIZATION OPTIONS        489

15.4         RELATED REPORTS         489

15.5         AUTHOR DETAILS           490

LIST OF TABLES

TABLE 1                EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS      44

TABLE 2                IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS  56

TABLE 3                EPIGENETICS MARKET: RISK ANALYSIS 59

TABLE 4                EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS       69

TABLE 5                AVERAGE SELLING PRICE TREND OF EPIGENETIC PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION)            77

TABLE 6                AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION)            80

TABLE 7                AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS AND REAGENTS,

BY REGION, 2022–2024 (USD MILLION)   80

TABLE 8                AVERAGE SELLING PRICE TREND OF EPIGENETIC ENZYMES, BY REGION,

2022–2024 (USD MILLION)            80

TABLE 9                EPIGENETICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 86

TABLE 10              EPIGENETICS MARKET: INVESTMENT AND FUNDING SCENARIO OF KEY PLAYERS, 2022−2025            87

TABLE 11              EPIGENETICS MARKET: PATENTS FILED GLOBALLY, 2014−2024   90

TABLE 12              EPIGENETICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2024–2025     92

TABLE 13              IMPORT VALUE OF HS CODE 9027.50– COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)           93

TABLE 14              IMPORT VALUE OF HS CODE 382.00– COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)           93

TABLE 15              EXPORT VALUE OF HS CODE 9027.50 – COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)           94

TABLE 16              EXPORT VALUE OF HS CODE 3822.00 – COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)           95

TABLE 17              EPIGENETICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026                 96

TABLE 18              TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00  97

TABLE 19              KEY REGULATORY AGENCIES    98

TABLE 20              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 100

TABLE 21              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           101

TABLE 22              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 101

TABLE 23              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 102

TABLE 24              MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 102

TABLE 25              AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           103

TABLE 26              EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS            103

TABLE 27              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING              106

TABLE 28              KEY BUYING CRITERIA, BY END USER    107

TABLE 29              LIST OF COMPANIES IMPLEMENTING AI/GEN AI IN EPIGENETICS MARKET            109

TABLE 30              US ADJUSTED RECIPROCAL TARIFF RATES                 110

TABLE 31              EXPORTS AND IMPORTS, BY REGION, 2024–2025                 111

TABLE 32              KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO EPIGENETICS   112

TABLE 33              CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES            113

TABLE 34              EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 117

TABLE 35              EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            118

TABLE 36              EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION,

2023–2030 (USD MILLION)            119

TABLE 37              NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)                 119

TABLE 38              EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 39              ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 40              LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)                 121

TABLE 41              MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION,

2023–2030 (USD MILLION)            121

TABLE 42              GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)                 121

TABLE 43              EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)          122

TABLE 44              NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 45              EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 46              ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,

2023–2030 (USD MILLION)            124

TABLE 47              LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,

2023–2030 (USD MILLION)            124

TABLE 48              MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION,

2023–2030 (USD MILLION)            124

TABLE 49              GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY,

2023–2030 (USD MILLION)            125

TABLE 50              EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)                 126

TABLE 51              NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 126

TABLE 52              EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               127

TABLE 53              ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)            127

TABLE 54              LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 128

TABLE 55              MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 128

TABLE 56              GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 128

TABLE 57              EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS,

BY REGION, 2023–2030 (USD MILLION)   129

TABLE 58              NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       130

TABLE 59              EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)            130

TABLE 60              ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       131

TABLE 61              LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       131

TABLE 62              MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)       131

TABLE 63              GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       132

TABLE 64              EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)            133

TABLE 65              NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)     133

TABLE 66              EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)            134

TABLE 67              ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)     134

TABLE 68              LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)     135

TABLE 69              MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)          135

TABLE 70              GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)     135

TABLE 71              EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS,

BY REGION, 2023–2030 (USD MILLION)   136

TABLE 72              NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       137

TABLE 73              EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 137

TABLE 74              ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       138

TABLE 75              LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       138

TABLE 76              MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 138

TABLE 77              GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)       139

TABLE 78              EPIGENETICS MARKET FOR HISTONES, BY REGION, 2023–2030 (USD MILLION)          140

TABLE 79              NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 80             EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 81              ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 82              LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 83              MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION,

2023–2030 (USD MILLION)            142

TABLE 84              GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 85              EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION,

2023–2030 (USD MILLION)            144

TABLE 86              NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               144

TABLE 87              EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)                 145

TABLE 88              ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)            145

TABLE 89              LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               146

TABLE 90              MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)            146

TABLE 91              GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               146

TABLE 92              EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)            147

TABLE 93              EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2023–2030 (USD MILLION)          147

TABLE 94              NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 95              EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 96              ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            149

TABLE 97              LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            149

TABLE 98              MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION,

2023–2030 (USD MILLION)            149

TABLE 99              GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 100            EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION,

2023–2030 (USD MILLION)            151

TABLE 101            NORTH AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               151

TABLE 102            EUROPE: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)                 152

TABLE 103            ASIA PACIFIC: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               152

TABLE 104            LATIN AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               153

TABLE 105            MIDDLE EAST: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION, 2023–2030 (USD MILLION)            153

TABLE 106            GCC COUNTRIES: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               153

TABLE 107            EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION,

2023–2030 (USD MILLION)            154

TABLE 108            NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               155

TABLE 109            EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               155

TABLE 110            ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               156

TABLE 111            LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               156

TABLE 112            MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,

BY REGION, 2023–2030 (USD MILLION)   156

TABLE 113            GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES,

BY COUNTRY, 2023–2030 (USD MILLION)               157

TABLE 114            EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION,

2023–2030 (USD MILLION)            157

TABLE 115            NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)                 158

TABLE 116            EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            158

TABLE 117            ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY,

2023–2030 (USD MILLION)            159

TABLE 118            LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)                 159

TABLE 119            MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION,

2023–2030 (USD MILLION)            159

TABLE 120            GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)                 160

TABLE 121            EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION,

2023–2030 (USD MILLION)            161

TABLE 122            NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,

BY COUNTRY, 2023–2030 (USD MILLION)               161

TABLE 123            EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 124            ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 125            LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 126            MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,

BY REGION, 2023–2030 (USD MILLION)   163

TABLE 127            GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 128            EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2023–2030 (USD MILLION)          164

TABLE 129            NORTH AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 130            EUROPE: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 131            ASIA PACIFIC: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 132            LATIN AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 133            MIDDLE EAST: EPIGENETICS MARKET FOR SOFTWARE, BY REGION,

2023–2030 (USD MILLION)            166

TABLE 134            REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)            167

TABLE 135            EPIGENETICS MARKET FOR SERVICES, BY REGION, 2023–2030 (USD MILLION)          168

TABLE 136            NORTH AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            168

TABLE 137            EUROPE: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            169

TABLE 138            ASIA PACIFIC: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            169

TABLE 139            LATIN AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            170

TABLE 140            MIDDLE EAST: EPIGENETICS MARKET FOR SERVICES, BY REGION,

2023–2030 (USD MILLION)            170

TABLE 141            GCC COUNTRIES: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            170

TABLE 142            EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)       172

TABLE 143            EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION,

2023–2030 (USD MILLION)            174

TABLE 144            NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               174

TABLE 145            EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               175

TABLE 146            ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               175

TABLE 147            LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               176

TABLE 148            MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,

BY REGION, 2023–2030 (USD MILLION)   176

TABLE 149            GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               176

TABLE 150            EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2023–2030 (USD MILLION)          178

TABLE 151            NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,

2023–2030 (USD MILLION)            178

TABLE 152            EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,

2023–2030 (USD MILLION)            179

TABLE 153            ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,

2023–2030 (USD MILLION)            179

TABLE 154            LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,

2023–2030 (USD MILLION)            180

TABLE 155            MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION,

2023–2030 (USD MILLION)            180

TABLE 156            GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,

2023–2030 (USD MILLION)            180

TABLE 157            EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION,

2023–2030 (USD MILLION)            182

TABLE 158            NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY,

BY COUNTRY, 2023–2030 (USD MILLION)               182

TABLE 159            EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 160            ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)                 183

TABLE 161            LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)                 184

TABLE 162            MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)                 184

TABLE 163            GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY,

BY COUNTRY, 2023–2030 (USD MILLION)               184

TABLE 164            EPIGENETICS MARKET FOR SONICATION, BY REGION, 2023–2030 (USD MILLION)          185

TABLE 165            NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,

2023–2030 (USD MILLION)            186

TABLE 166            EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,

2023–2030 (USD MILLION)            186

TABLE 167            ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,

2023–2030 (USD MILLION)            187

TABLE 168            LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,

2023–2030 (USD MILLION)            187

TABLE 169            MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION,

2023–2030 (USD MILLION)            187

TABLE 170            GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,

2023–2030 (USD MILLION)            188

TABLE 171            EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION,

2023–2030 (USD MILLION)            189

TABLE 172            NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY, 2023–2030 (USD MILLION)               189

TABLE 173            EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,

2023–2030 (USD MILLION)            190

TABLE 174            ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)            190

TABLE 175            LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)            191

TABLE 176            MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)                 191

TABLE 177            GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY, 2023–2030 (USD MILLION)               191

TABLE 178            EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION) 193

TABLE 179            EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION,

2023–2030 (USD MILLION)            194

TABLE 180            NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)                 194

TABLE 181            EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY,

2023–2030 (USD MILLION)            195

TABLE 182            ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)                 195

TABLE 183            LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)                 196

TABLE 184            MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION,

2023–2030 (USD MILLION)            196

TABLE 185            GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)                 196

TABLE 186            COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS             197

TABLE 187            EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION,

2023–2030 (USD MILLION)            198

TABLE 188            NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 189            EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 199

TABLE 190            ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            199

TABLE 191            LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               200

TABLE 192            MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2023–2030 (USD MILLION)            200

TABLE 193            GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               200

TABLE 194            EPIGENETICS MARKET FOR OTHER METHODS, BY REGION,

2023–2030 (USD MILLION)            201

TABLE 195            NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)                 201

TABLE 196            EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,

2023–2030 (USD MILLION)            202

TABLE 197            ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,

2023–2030 (USD MILLION)            202

TABLE 198            LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)                 203

TABLE 199            MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION,

2023–2030 (USD MILLION)            203

TABLE 200            GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)                 203

TABLE 201            EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       205

TABLE 202            EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS        206

TABLE 203            EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)          208

TABLE 204            NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            208

TABLE 205            EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            209

TABLE 206            ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            209

TABLE 207            LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            210

TABLE 208            MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)            210

TABLE 209            GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            210

TABLE 210            EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION,

2023–2030 (USD MILLION)            211

TABLE 211            NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 212

TABLE 212            EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY,

2023–2030 (USD MILLION)            212

TABLE 213            ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 213

TABLE 214            LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 213

TABLE 215            MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)                 213

TABLE 216            GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 214

TABLE 217            EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION,

2023–2030 (USD MILLION)            215

TABLE 218            NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            215

TABLE 219            EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            216

TABLE 220            ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            216

TABLE 221            LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            217

TABLE 222            MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION,

2023–2030 (USD MILLION)            217

TABLE 223            GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            217

TABLE 224            EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,

2023–2030 (USD MILLION)            218

TABLE 225            NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               219

TABLE 226            EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            219

TABLE 227            ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               220

TABLE 228            LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               220

TABLE 229            MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2023–2030 (USD MILLION)            220

TABLE 230            GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               221

TABLE 231            EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,

2023–2030 (USD MILLION)            222

TABLE 232            NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               222

TABLE 233            EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            223

TABLE 234            ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 235            LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               224

TABLE 236            MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,

BY REGION, 2023–2030 (USD MILLION)   224

TABLE 237            GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               224

TABLE 238            EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION,

2023–2030 (USD MILLION)            225

TABLE 239            NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            226

TABLE 240            EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            226

TABLE 241            ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            227

TABLE 242            LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            227

TABLE 243            MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)                 227

TABLE 244            GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            228

TABLE 245          EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)            230

TABLE 246            EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY REGION, 2023–2030 (USD MILLION)   231

TABLE 247            NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     231

TABLE 248            EUROPE: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 232

TABLE 249            ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       232

TABLE 250            LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     233

TABLE 251            MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)            233

TABLE 252            GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     233

TABLE 253            EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          235

TABLE 254            NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   235

TABLE 255            EUROPE: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     236

TABLE 256            ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     236

TABLE 257            LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   237

TABLE 258            MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)        237

TABLE 259            GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   237

TABLE 260            EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY REGION,

2023–2030 (USD MILLION)            239

TABLE 261            NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               239

TABLE 262            EUROPE: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               240

TABLE 263            ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               240

TABLE 264            LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               241

TABLE 265            MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS,

BY REGION, 2023–2030 (USD MILLION)   241

TABLE 266            GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               241

TABLE 267            EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,

BY REGION, 2023–2030 (USD MILLION)   242

TABLE 268            NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     243

TABLE 269            EUROPE: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       243

TABLE 270            ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            244

TABLE 271            LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     244

TABLE 272            MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)          244

TABLE 273            GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     245

TABLE 274            EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)            247

TABLE 275            EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          248

TABLE 276            NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   248

TABLE 277            EUROPE: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     249

TABLE 278            ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     249

TABLE 279            LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   250

TABLE 280            MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          250

TABLE 281            GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               250

TABLE 282            EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY REGION, 2023–2030 (USD MILLION)   251

TABLE 283            NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     252

TABLE 284            EUROPE: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 252

TABLE 285            ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       253

TABLE 286            LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     253

TABLE 287            MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)       253

TABLE 288            GCC COUNTRIES: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     254

TABLE 289            EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY REGION,

2023–2030 (USD MILLION)            255

TABLE 290            NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               255

TABLE 291            EUROPE: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               256

TABLE 292            ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               256

TABLE 293            LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 294            MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS,

BY REGION, 2023–2030 (USD MILLION)   257

TABLE 295            GCC COUNTRIES: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 296            EPIGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION) 259

TABLE 297            NORTH AMERICA: KEY MACROECONOMIC INDICATORS      260

TABLE 298            NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            261

TABLE 299            NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            262

TABLE 300            NORTH AMERICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            262

TABLE 301            NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            263

TABLE 302            NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            263

TABLE 303            NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       264

TABLE 304            NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            264

TABLE 305            NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            265

TABLE 306            NORTH AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            265

TABLE 307            NORTH AMERICA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            266

TABLE 308            US: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)       267

TABLE 309            US: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)                267

TABLE 310            US: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            268

TABLE 311            US: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)                268

TABLE 312            US: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       269

TABLE 313            US: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            269

TABLE 314            US: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            269

TABLE 315            US: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)                270

TABLE 316            US: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)                270

TABLE 317            CANADA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            271

TABLE 318            CANADA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            271

TABLE 319            CANADA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            272

TABLE 320            CANADA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            272

TABLE 321            CANADA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            273

TABLE 322            CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            273

TABLE 323            CANADA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              274

TABLE 324            CANADA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            274

TABLE 325            CANADA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            275

TABLE 326            EUROPE: KEY MACROECONOMIC INDICATORS                 276

TABLE 327            EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            277

TABLE 328            EUROPE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            277

TABLE 329          EUROPE: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            277

TABLE 330            EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 331            EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 332            EUROPE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            279

TABLE 333            EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            279

TABLE 334            EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              280

TABLE 335            EUROPE: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            280

TABLE 336            EUROPE: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            281

TABLE 337            GERMANY: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     281

TABLE 338            GERMANY: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            282

TABLE 339            GERMANY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            282

TABLE 340            GERMANY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            283

TABLE 341          GERMANY: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            283

TABLE 342            GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            283

TABLE 343            GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              284

TABLE 344            GERMANY: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            284

TABLE 345            GERMANY: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            285

TABLE 346            UK: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)       286

TABLE 347            UK: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)                286

TABLE 348            UK: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            287

TABLE 349            UK: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)                287

TABLE 350            UK: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       288

TABLE 351            UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            288

TABLE 352            UK: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            289

TABLE 353            UK: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)                289

TABLE 354            UK: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)                290

TABLE 355            FRANCE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            291

TABLE 356          FRANCE: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 357            FRANCE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            292

TABLE 358            FRANCE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            292

TABLE 359            FRANCE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            293

TABLE 360            FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            293

TABLE 361            FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              294

TABLE 362            FRANCE: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            294

TABLE 363            FRANCE: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            295

TABLE 364            ITALY: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            296

TABLE 365            ITALY: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            296

TABLE 366            ITALY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            297

TABLE 367            ITALY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)         297

TABLE 368            ITALY: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            298

TABLE 369            ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            298

TABLE 370            ITALY: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              299

TABLE 371            ITALY: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            299

TABLE 372            ITALY: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)                300

TABLE 373            SPAIN: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            300

TABLE 374            SPAIN: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            301

TABLE 375            SPAIN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            301

TABLE 376            SPAIN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            302

TABLE 377            SPAIN: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            302

TABLE 378            SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            302

TABLE 379            SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              303

TABLE 380            SPAIN: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            303

TABLE 381            SPAIN: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)                304

TABLE 382            REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            304

TABLE 383            REST OF EUROPE: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            305

TABLE 384            REST OF EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            305

TABLE 385            REST OF EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            306

TABLE 386            REST OF EUROPE: EPIGENETICS MARKET, BY METHOD,

2023–2030 (USD MILLION)            306

TABLE 387            REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            306

TABLE 388            REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            307

TABLE 389            REST OF EUROPE: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            307

TABLE 390            REST OF EUROPE: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            308

TABLE 391            ASIA PACIFIC: KEY MACROECONOMIC INDICATORS      309

TABLE 392            ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     311

TABLE 393            ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     311

TABLE 394            ASIA PACIFIC: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            312

TABLE 395            ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            312

TABLE 396            ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            313

TABLE 397            ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       313

TABLE 398            ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            313

TABLE 399            ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            314

TABLE 400          ASIA PACIFIC: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            314

TABLE 401            ASIA PACIFIC: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            315

TABLE 402            CHINA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            316

TABLE 403            CHINA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            316

TABLE 404            CHINA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            317

TABLE 405            CHINA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            317

TABLE 406            CHINA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            318

TABLE 407            CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            318

TABLE 408            CHINA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              319

TABLE 409            CHINA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            319

TABLE 410            CHINA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            320

TABLE 411            JAPAN: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            321

TABLE 412            JAPAN: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            321

TABLE 413            JAPAN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            322

TABLE 414            JAPAN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            322

TABLE 415            JAPAN: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            323

TABLE 416            JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            323

TABLE 417            JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              324

TABLE 418            JAPAN: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            324

TABLE 419            JAPAN: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            325

TABLE 420            INDIA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            326

TABLE 421            INDIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            326

TABLE 422            INDIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 423            INDIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)         327

TABLE 424            INDIA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            328

TABLE 425            INDIA: EPIGENETICS MARKET, BY TECHNOLOGY 2023–2030 (USD MILLION)             328

TABLE 426            INDIA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              329

TABLE 427            INDIA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            329

TABLE 428            INDIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)                330

TABLE 429            AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     330

TABLE 430            AUSTRALIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            331

TABLE 431            AUSTRALIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            331

TABLE 432            AUSTRALIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            332

TABLE 433            AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       332

TABLE 434            AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            332

TABLE 435            AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              333

TABLE 436            AUSTRALIA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            333

TABLE 437            AUSTRALIA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            334

TABLE 438            SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     334

TABLE 439            SOUTH KOREA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            335

TABLE 440            SOUTH KOREA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            335

TABLE 441            SOUTH KOREA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            336

TABLE 442            SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       336

TABLE 443            SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            336

TABLE 444            SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            337

TABLE 445            SOUTH KOREA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            337

TABLE 446          SOUTH KOREA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            338

TABLE 447            REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            338

TABLE 448            REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)          339

TABLE 449            REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)                 339

TABLE 450            REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            340

TABLE 451            REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD,

2023–2030 (USD MILLION)            340

TABLE 452            REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            340

TABLE 453            REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            341

TABLE 454            REST OF ASIA PACIFIC: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            341

TABLE 455            REST OF ASIA PACIFIC: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            342

TABLE 456            LATIN AMERICA: KEY MACROECONOMIC INDICATORS      343

TABLE 457            LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     343

TABLE 458            LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     343

TABLE 459            LATIN AMERICA: EPIGENETICS MARKET, BY TYPE, 2023–2030 (USD MILLION)                344

TABLE 460            LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            344

TABLE 461            LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            345

TABLE 462            LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       345

TABLE 463            LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            345

TABLE 464            LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            346

TABLE 465            LATIN AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            346

TABLE 466            LATIN AMERICA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            347

TABLE 467            BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            347

TABLE 468            BRAZIL: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            348

TABLE 469            BRAZIL: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            348

TABLE 470            BRAZIL: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            349

TABLE 471            BRAZIL: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            349

TABLE 472            BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            349

TABLE 473            BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              350

TABLE 474            BRAZIL: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            350

TABLE 475            BRAZIL: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            351

TABLE 476            MEXICO: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            351

TABLE 477          MEXICO: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            352

TABLE 478            MEXICO: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            352

TABLE 479            MEXICO: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            353

TABLE 480            MEXICO: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            353

TABLE 481            MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            353

TABLE 482            MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              354

TABLE 483            MEXICO: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            354

TABLE 484            MEXICO: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            355

TABLE 485            REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            355

TABLE 486            REST OF LATIN AMERICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            356

TABLE 487            REST OF LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)            356

TABLE 488            REST OF LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            357

TABLE 489            REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD,

2023–2030 (USD MILLION)            357

TABLE 490            REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            357

TABLE 491            REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            358

TABLE 492            REST OF LATIN AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            358

TABLE 493            REST OF LATIN AMERICA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            359

TABLE 494            MIDDLE EAST: KEY MACROECONOMIC INDICATORS      360

TABLE 495            MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION)          360

TABLE 496            MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     361

TABLE 497            MIDDLE EAST: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            361

TABLE 498            MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            362

TABLE 499            MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            362

TABLE 500            MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       363

TABLE 501            MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            363

TABLE 502            MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            364

TABLE 503            MIDDLE EAST: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            364

TABLE 504            MIDDLE EAST: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            365

TABLE 505            GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            365

TABLE 506            GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            366

TABLE 507            GCC COUNTRIES: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            366

TABLE 508            GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            367

TABLE 509            GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            367

TABLE 510            GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       368

TABLE 511            GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            368

TABLE 512            GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            369

TABLE 513            GCC COUNTRIES: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            369

TABLE 514            GCC COUNTRIES: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            370

TABLE 515            SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)     371

TABLE 516            SAUDI ARABIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            371

TABLE 517            SAUDI ARABIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            372

TABLE 518            SAUDI ARABIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            372

TABLE 519            SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       373

TABLE 520            SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            373

TABLE 521            SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            374

TABLE 522            SAUDI ARABIA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            374

TABLE 523            SAUDI ARABIA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            375

TABLE 524            UAE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            375

TABLE 525            UAE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)                376

TABLE 526            UAE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            376

TABLE 527            UAE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)                377

TABLE 528            UAE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)       377

TABLE 529            UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            377

TABLE 530            UAE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            378

TABLE 531            UAE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)                378

TABLE 532            UAE: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)                379

TABLE 533            REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            379

TABLE 534            REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            380

TABLE 535            REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)            380

TABLE 536            REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            381

TABLE 537            REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD,

2023–2030 (USD MILLION)            381

TABLE 538            REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            381

TABLE 539            REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            382

TABLE 540            REST OF GCC COUNTRIES: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            382

TABLE 541            REST OF GCC COUNTRIES: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            383

TABLE 542            REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING,

2023–2030 (USD MILLION)            383

TABLE 543            REST OF MIDDLE EAST: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            384

TABLE 544            REST OF MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)                 384

TABLE 545            REST OF MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            385

TABLE 546            REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD,

2023–2030 (USD MILLION)            385

TABLE 547            REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            385

TABLE 548            REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            386

TABLE 549            REST OF MIDDLE EAST: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            386

TABLE 550            REST OF MIDDLE EAST: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            387

TABLE 551            AFRICA: KEY MACROECONOMIC INDICATORS                 388

TABLE 552            AFRICA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)            388

TABLE 553            AFRICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE,

2023–2030 (USD MILLION)            389

TABLE 554            AFRICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE,

2023–2030 (USD MILLION)            389

TABLE 555            AFRICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE,

2023–2030 (USD MILLION)            390

TABLE 556            AFRICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)            390

TABLE 557            AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            390

TABLE 558            AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              391

TABLE 559            AFRICA: EPIGENETICS PRODUCT MARKET, BY END USER,

2023–2030 (USD MILLION)            391

TABLE 560            AFRICA: EPIGENETICS SERVICE MARKET, BY END USER,

2023–2030 (USD MILLION)            392

TABLE 561            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, JANUARY 2022–JULY 2025                 393

TABLE 562            EPIGENETICS MARKET: DEGREE OF COMPETITION 396

TABLE 563            EPIGENETICS MARKET: REGION FOOTPRINT                 403

TABLE 564            EPIGENETICS MARKET: OFFERING FOOTPRINT                 403

TABLE 565            EPIGENETICS MARKET: METHOD FOOTPRINT                 404

TABLE 566            EPIGENETICS MARKET: TECHNOLOGY FOOTPRINT       405

TABLE 567            EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES              408

TABLE 568            EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES          409

TABLE 569            EPIGENETICS MARKET: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025               410

TABLE 570            EPIGENETICS MARKET: DEALS, JANUARY 2022–JULY 2025             411

TABLE 571            EPIGENETICS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025          412

TABLE 572            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          413

TABLE 573            THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED             414

TABLE 574            THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,

JANUARY 2022–JULY 2025               416

TABLE 575            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025               417

TABLE 576            ILLUMINA, INC.: COMPANY OVERVIEW 418

TABLE 577            ILLUMINA, INC.: PRODUCTS OFFERED  419

TABLE 578            ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025               421

TABLE 579            ILLUMINA, INC.: DEALS, JANUARY 2022–JULY 2025        421

TABLE 580            MERCK KGAA: COMPANY OVERVIEW     423

TABLE 581            MERCK KGAA: PRODUCTS OFFERED      424

TABLE 582            PACBIO: COMPANY OVERVIEW 427

TABLE 583            PACBIO: PRODUCTS OFFERED  428

TABLE 584            PACBIO: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025             429

TABLE 585            PACBIO: DEALS, JANUARY 2022–JULY 2025                 430

TABLE 586            PACBIO: EXPANSIONS, JANUARY 2022– JULY 2025                 430

TABLE 587            DANAHER: COMPANY OVERVIEW            432

TABLE 588            DANAHER: PRODUCTS OFFERED             433

TABLE 589            DANAHER: DEALS, JANUARY 2022–JULY 2025                 435

TABLE 590            BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW          436

TABLE 591            BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED             437

TABLE 592            ACTIVE MOTIF: COMPANY OVERVIEW  441

TABLE 593            ACTIVE MOTIF: PRODUCTS OFFERED   441

TABLE 594            ACTIVE MOTIF: DEALS, JANUARY 2022–JULY 2025        444

TABLE 595            NEW ENGLAND BIOLABS: COMPANY OVERVIEW                 445

TABLE 596            NEW ENGLAND BIOLABS: PRODUCTS OFFERED                 445

TABLE 597          NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025               447

TABLE 598            NEW ENGLAND BIOLABS: DEALS, JANUARY 2022–JULY 2025  448

TABLE 599            QIAGEN: COMPANY OVERVIEW 449

TABLE 600            QIAGEN: PRODUCTS OFFERED 450

TABLE 601            QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025             451

TABLE 602            ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW          452

TABLE 603            ZYMO RESEARCH CORPORATION: PRODUCTS OFFERED             452

TABLE 604            ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES,

JANUARY 2022–JULY 2025               455

TABLE 605            ZYMO RESEARCH CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025               455

TABLE 606            ZYMO RESEARCH CORPORATION: OTHER DEVELOPMENTS,

JANUARY 2022–JULY 2025               455

TABLE 607            REVVITY: COMPANY OVERVIEW               456

TABLE 608            REVVITY: PRODUCTS OFFERED                457

TABLE 609            REVVITY: DEALS, JANUARY 2022–JULY 2025                 458

TABLE 610            HOLOGIC, INC. COMPANY OVERVIEW   459

TABLE 611            HOLOGIC, INC.: PRODUCTS OFFERED   460

TABLE 612            F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW          463

TABLE 613            F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED             464

TABLE 614            PROMEGA CORPORATION: COMPANY OVERVIEW          466

TABLE 615            PROMEGA CORPORATION: PRODUCTS OFFERED             466

TABLE 616            EPIGENTEK GROUP INC.: COMPANY OVERVIEW                 468

TABLE 617            EPIGENTEK GROUP INC.: PRODUCTS OFFERED                 468

TABLE 618            EPICYPHER: COMPANY OVERVIEW          472

TABLE 619            FIOS GENOMICS: COMPANY OVERVIEW                 473

TABLE 620            GENOMESCAN: COMPANY OVERVIEW   474

TABLE 621            CREATIVE BIOGENE: COMPANY OVERVIEW                 475

TABLE 622            BPS BIOSCIENCE, INC.: COMPANY OVERVIEW                 475

TABLE 623            ABNOVA CORPORATION: COMPANY OVERVIEW                 477

TABLE 624            CREATIVE DIAGNOSTICS: COMPANY OVERVIEW          478

TABLE 625            BIOMODAL: COMPANY OVERVIEW          479

TABLE 626            INTEGRATED DNA TECHNOLOGIES, INC.: COMPANY OVERVIEW   480

TABLE 627            NOVOGENE CO., LTD.: COMPANY OVERVIEW                 481

LIST OF FIGURES

FIGURE 1              EPIGENETICS MARKET SEGMENTATION AND REGIONAL SCOPE            43

FIGURE 2              EPIGENETICS MARKET: YEARS CONSIDERED                 44

FIGURE 3              EPIGENETICS MARKET: RESEARCH DESIGN                 47

FIGURE 4              EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES          49

FIGURE 5              EPIGENETICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024  50

FIGURE 6              EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024                 51

FIGURE 7              ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:

REVENUE ANALYSIS, 2024             51

FIGURE 8              EPIGENETICS MARKET: INSIGHTS FROM PRIMARY EXPERTS          53

FIGURE 9              SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH          53

FIGURE 10            EPIGENETICS MARKET: CAGR PROJECTIONS                 55

FIGURE 11            EPIGENETICS MARKET: DATA TRIANGULATION                 57

FIGURE 12            EPIGENETICS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)       60

FIGURE 13            EPIGENETICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)                61

FIGURE 14            EPIGENETICS MARKET, BY METHOD, 2025 VS. 2030 (USD MILLION)       61

FIGURE 15            EPIGENETICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)                62

FIGURE 16           EPIGENETICS PRODUCT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      62

FIGURE 17            EPIGENETICS SERVICE MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      63

FIGURE 18            GEOGRAPHIC ANALYSIS OF EPIGENETICS MARKET               64

FIGURE 19            TECHNOLOGICAL ADVANCEMENTS IN EPIGENETICS RESEARCH TO

DRIVE MARKET GROWTH            65

FIGURE 20            DNA METHYLATION SEGMENT AND US LED NORTH AMERICAN EPIGENETICS MARKET IN 2024           66

FIGURE 21            ACADEMIC & RESEARCH INSTITUTES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    66

FIGURE 22            ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL EPIGENETICS MARKET DURING FORECAST PERIOD                67

FIGURE 23            EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES     68

FIGURE 24            COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2022                70

FIGURE 25            NUMBER OF CANCER CASES IN US, 2019–2024                 73

FIGURE 26            REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN

EPIGENETICS MARKET  77

FIGURE 27            AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)               78

FIGURE 28            AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER, 2024 (USD)                 79

FIGURE 29            AVERAGE SELLING PRICE OF ENZYMES, BY KEY PLAYER, 2024 (USD)        79

FIGURE 30            AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)    81

FIGURE 31            AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY REGION,

2024 (USD MILLION)       81

FIGURE 32            AVERAGE SELLING PRICE OF ENZYMES, BY REGION, 2024 (USD MILLION)    82

FIGURE 33            EPIGENETICS MARKET: VALUE CHAIN ANALYSIS            83

FIGURE 34            EPIGENETICS MARKET: ECOSYSTEM ANALYSIS                 86

FIGURE 35            EPIGENETICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025 88

FIGURE 36            EPIGENETICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 91

FIGURE 37            EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS            104

FIGURE 38            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING              106

FIGURE 39            KEY BUYING CRITERIA, BY END USER    107

FIGURE 40            EPIGENETICS MARKET: AI USE CASES    108

FIGURE 41            EPIGENETICS MARKET, BY OFFERING, 2023–2030 (MILLION UNITS)             117

FIGURE 42            NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT          261

FIGURE 43            ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT          310

FIGURE 44            EPIGENETICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024                395

FIGURE 45            EPIGENETICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024   396

FIGURE 46            EV/EBITDA OF KEY VENDORS   398

FIGURE 47            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            398

FIGURE 48            EPIGENETICS MARKET: BRAND/PRODUCT COMPARISON   399

FIGURE 49            EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024         401

FIGURE 50            EPIGENETICS MARKET: COMPANY FOOTPRINT                 402

FIGURE 51            EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 407

FIGURE 52            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             414

FIGURE 53            ILLUMINA, INC.: COMPANY SNAPSHOT (2024)                 419

FIGURE 54            MERCK KGAA: COMPANY SNAPSHOT (2024)                 424

FIGURE 55            PACBIO: COMPANY SNAPSHOT (2024)    428

FIGURE 56            DANAHER: COMPANY SNAPSHOT (2024)                 433

FIGURE 57            BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)             437

FIGURE 58            QIAGEN: COMPANY SNAPSHOT (2024)   450

FIGURE 59            REVVITY: COMPANY SNAPSHOT (2024)  457

FIGURE 60            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 460

FIGURE 61            F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)             464

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧